Endometrial Neoplasms
114
22
32
40
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
15 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.8%
10 terminated out of 114 trials
80.0%
-6.6% vs benchmark
8%
9 trials in Phase 3/4
38%
15 of 40 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 40 completed trials
Clinical Trials (114)
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A Study of DM002 in Patients With Advanced Solid Tumors
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
A Study of LY4175408 in Participants With Advanced Cancer
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors